Moleculin Bio up on filing new patent for Covid-19 drug candidate

Moleculin Biotech (NASDAQ:MBRX) has filed a new patent application covering the use of WP1122 and its analogs as therapies to limit the ability of coronavirus and other viruses to replicate.

The patent application covers joint discoveries which came as a result of an ongoing sponsored research agreement.

This patent application coincided with Moleculin entering into an agreement with a major Texas university to conduct research on WP1122.

https://seekingalpha.com/news/3553713-moleculin-bioplus-15-premarket-on-filing-new-patent-for-covidminus-19-drug-candidate